Luca Gianni, MD, on Evaluating Progress With Checkpoint Inhibitors in Breast Cancer

Posted: Friday, January 17, 2020

Luca Gianni, MD, of the Fondazione Michelangelo, talks about the implications of his study on neoadjuvant atezolizumab and whether it represents the best setting for immune checkpoint inhibitors in patients with triple-negative breast cancer.